Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleniglipron in Participants With Obesity or Overweight
NCT06693843Phase 2Completed
- Sponsor
- Gasherbrum Bio
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aleniglipron in obesity (7 cohorts), sponsored by Gasherbrum Bio. Primary endpoints: Percent change in body weight at 36 weeks, Treatment-Emergent Adverse Events and Serious Adverse Events at 72 weeks and 4 more. Started Oct 2024; status: completed.
02
Drugs
aleniglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06693843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693843.